Overman, M J <br/><br/>
The addition of rituximab to CHOP chemotherapy improves overall and failure-free survival for follicular grade 3 lymphoma.  [electronic resource] 

 -  Annals of oncology : official journal of the European Society for Medical Oncology  Mar 2008 
 - 553-9 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1569-8041 
<br/><br/><label>Standard No.: </label>10.1093/annonc/mdm511  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antibodies, Monoclonal--administration & dosage<br/>Antibodies, Monoclonal, Murine-Derived<br/>Antineoplastic Combined Chemotherapy Protocols--administration & dosage<br/>Cohort Studies<br/>Cyclophosphamide--administration & dosage<br/>Disease-Free Survival<br/>Doxorubicin--administration & dosage<br/>Female<br/>Follow-Up Studies<br/>Humans<br/>Lymphoma, Follicular--drug therapy<br/>Male<br/>Middle Aged<br/>Prednisone--administration & dosage<br/>Proportional Hazards Models<br/>Rituximab<br/>Salvage Therapy<br/>Survival Rate<br/>Vincristine--administration & dosage